Page 351 - Read Online

Page 16 of 20 Smigiel et al. J Cancer Metastasis Treat 2019;5:47 I http://dx.doi.org/10.20517/2394-4722.2019.26

118. Westcott JM, Prechtl AM, Maine EA, Dang TT, Esparza MA, et al. An epigenetically distinct breast cancer cell subpopulation promotes
collective invasion. J Clin Invest 2015;125:1927-43.
119. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. Circulating tumor cells, disease progression, and survival in metastatic
breast cancer. N Engl J Med 2004;351:781-91.
120. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed
metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
121. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, et al. Circulating tumor cells versus imaging--predicting overall survival in
metastatic breast cancer. Clin Cancer Res 2006;12:6403-9.
122. Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, et al. Development of circulating tumor cell-endocrine therapy index in
patients with hormone receptor–positive breast cancer. Clinical Cancer Res 2015;21:2487-98.
123. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, et al. Circulating tumor cells: a useful predictor of treatment efficacy in
metastatic breast cancer. J Clin Oncol 2009;27:5153-9.
124. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, et al. Circulating tumor cells with a putative stem cell phenotype
in peripheral blood of patients with breast cancer. Cancer Lett 2010;288:99-106.
125. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, et al. Epithelial to mesenchymal transition markers expressed in
circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 2011;13:R59.
126. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and
mesenchymal composition. Science 2013;339:580-4.
127. Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, et al. Co-expression of putative stemness and epithelial-to-
mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer
2014;14:651.
128. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, et al. Identification of a population of blood circulating tumor cells
from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
129. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
130. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer
Cell 2003;3:537-49.
131. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, et al. TGFbeta primes breast tumors for lung metastasis seeding through
angiopoietin-like 4. Cell 2008;133:66-77.
132. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, et al. Distinct organ-specific metastatic potential of individual breast cancer cells
and primary tumors. J Clin Invest 2005;115:44-55.
133. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
134. Shibue T, Weinberg RA. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment.
Semin Cancer Biol 2011;21:99-106.
135. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, et al. Interactions between cancer stem cells and their niche govern
metastatic colonization. Nature 2011;481:85-9.
136. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, et al. Cancer stem cells from human breast tumors are involved in spontaneous
metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 2010;107:18115-20.
137. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, et al. Single-cell analysis reveals a stem-cell program in human metastatic
breast cancer cells. Nature 2015;526:131-5.
138. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells.
Proc Natl Acad Sci U S A 2003;100:3983-8.
139. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. ALDH1 is a marker of normal and malignant human mammary
stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67.
140. Kim W-T, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Reports 2017;50:285-98.
141. Liu S, Cong Y, Wang D, Sun Y, Deng L, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective
of their normal counterparts. Stem Cell Reports 2014;2:78-91.
142. Malladi S, Macalinao DG, Jin X, He L, Basnet H, et al. Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT.
Cell 2016;165:45-60.
143. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol
2017;14:611-29.
144. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. The epithelial-mesenchymal transition generates cells with properties of stem
cells. Cell 2008;133:704-15.
145. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. Generation of breast cancer stem cells through epithelial-mesenchymal
transition. PLoS One 2008;3:e2888.
146. Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, et al. EMT inducers catalyze malignant transformation of mammary
epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet 2012;8:e1002723.
147. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity
and enhances tumorigenicity. Cell 2013;154:61-74.
148. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem 2013;59:168-79.
149. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, et al. Normal and neoplastic nonstem cells can spontaneously convert to
a stem-like state. Proc Natl Acad Sci U S A 2011;108:7950-5.